Depression Patch Approved, to be Sold as Emsam
Federal regulators in the US have approved the world’s first antidepressant skin patch, the selegiline transdermal patch, to be marketed under the name ‘Emsam’. The drug, first approved in the 1980s to help treat Parkinson’s disease, belongs to a category of less frequently used antidepressants prone to interactions with a substance called tyramine. The antidepressant patch will carry a ‘black box’ warning from the FDA.
Following the methylphenidate transdermal patch for ADHD (see our earlier articles and “ADHD Patch to be Sold as Daytrana”), the latest drug and patch delivery system to receive FDA approval is the selegiline transdermal patch for the treatment of depression.
According to a story carried by the APA’s PsycPort, the antidepressant skin patch was approved on Tuesday and will be marketed under the name ‘Emsam’. The APA article highlights the risks of drugs which fall into the same category as Emsam, the monoamine oxidase inhibitors (MAOIs):
Although health officials say MAOIs are safe when used correctly, the drugs can cause dangerous interactions, including sudden and severe rises in blood pressure that can lead to a stroke, when patients consume food or drinks that contain a substance called tyramine – found in draft beer, red wine, fava beans, salamis, aged cheeses, soy sauce and other products.
However, the news release provided directly by the FDA specifically mentions that:
The once a day patch works by delivering selegiline, a monoamine oxidase inhibitor or MAOI, through the skin and into the bloodstream. At its lowest strength, Emsam can be used without the dietary restrictions that are needed for all oral MAO inhibitors that are approved for treating major depression.
“Emsam provides a significant advance because at least in its lowest dose patients can use the drug without the usual dietary restrictions associated with these types of drugs known as MAO inhibitors,” said Dr. Steven Galson, Director for the Center for Drug Evaluation and Research.
The FDA news release continues:
MAO inhibitors usually require specific dietary restrictions because when combined with certain foods they can cause a sudden, large increase in blood pressure, or “hypertensive crisis”. A hypertensive crisis can lead to a stroke and death. Symptoms of a hypertensive crisis include sudden onset of severe headache, nausea, stiff neck, a fast heartbeat or a change in the way your heart beats (palpitations), sweating, and confusion. Patients who have these symptoms should get medical care right away.
The lowest dose of the MAOI patch, which delivers 6 milligrams (mg) of the medication over a 24 hour period, can be used without such dietary restrictions.
The FDA reports that the only common side effect of Emsam detected in placebo-controlled trials was a mild skin reaction where the patch was placed. The antidepressant patch will be made available in three sizes that deliver 6, 9, or 12 mg of selegiline per 24 hours.
6 Responses to “Depression Patch Approved, to be Sold as Emsam”
The comments form is currently closed, but you can click to read the comments left previously on “Depression Patch Approved, to be Sold as Emsam”.
